MedPath

A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

Phase 3
Completed
Conditions
Overactive Bladder
Registration Number
NCT00189800
Lead Sponsor
Astellas Pharma Inc
Brief Summary

The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Symptoms of overactive bladder
  • Must be able to complete the micturition diary
Read More
Exclusion Criteria
  • Pregnant or lactating
  • Clinically significant outflow obstruction
  • Significant post void residual urine
  • Significant stress incontinence
  • Urinary tract infection
  • Chronic inflammation
  • Bladder stones
  • Previous pelvic radiation therapy
  • Previous or current malignant disease of the pelvic organs
  • Uncontrolled narrow angle glaucoma
  • Urinary or gastric retention
  • Electrostimulation therapy
  • Bladder training
  • Diabetic neuropathy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath